CommercialPrior AuthMedium impact
Belimumab (Benlysta®)
BCBS Tennessee·TN · Rheumatology, Nephrology·Medical Policy
Effective date
Sep 30, 2026
We identified it
Jul 17, 2026
Summary
BlueCross BlueShield of Tennessee is implementing a new medical policy for Belimumab (Benlysta®) effective September 30, 2026, covering treatment of active systemic lupus erythematosus (SLE) and active lupus nephritis in patients 5 years and older. Coverage requires prior authorization, specific autoantibody testing, concurrent standard therapy, and prescriber specialty validation (rheumatology/nephrology). The policy excludes severe active CNS lupus and concurrent biologic use.
Action Required
By September 30, 2026: Billing team must implement prior authorization requirement for Belimumab (J0490) in the billing system for BlueCross BlueShield of Tennessee commercial and state mandate plans. Update prior auth rules to require: (1) confirmation of SLE or lupus nephritis diagnosis with positive autoantibody documentation (ANA, anti-dsDNA, anti-Sm, or antiphospholipid antibodies) or kidney biopsy; (2) evidence member is on concurrent standard therapy (glucocorticoids, antimalarials, or immunosuppressants); (3) prescriber specialty validation (rheumatologist, nephrologist, or SLE specialist); (4) confirmation patient is 5+ years old; (5) exclusion screening for severe active CNS lupus or concurrent biologic therapy. Configure system to deny claims if: prior auth not obtained, required documentation missing, prescriber specialty incorrect, or exclusion criteria present. Training required for billing staff to recognize Benlysta prior auth flags and route appropriately to clinical reviewers.